Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile

Pedram Rafiei, Azita Haddadi Division of Pharmacy, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada Abstract: Docetaxel is a highly potent anticancer agent being used in a wide spectrum of cancer types. There are important matters of concern regarding the drug&a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rafiei P, Haddadi A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Poly (lactide-co-glycolide) (PLGA) poly (lactide-co-glycolide)-poly (ethylene glycol) (PLGA-PEG) polymeric nanoparticles docetaxel emulsification solvent evaporation sustained release Pharmacokinetics bio-distribution. Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/3411511e40d34317aeb3db91e9526674
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3411511e40d34317aeb3db91e9526674
record_format	dspace
spelling	oai:doaj.org-article:3411511e40d34317aeb3db91e95266742021-12-02T02:56:03ZDocetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile1178-2013https://doaj.org/article/3411511e40d34317aeb3db91e95266742017-01-01T00:00:00Zhttps://www.dovepress.com/docetaxel-loaded-plga-and-plga-peg-nanoparticles-for-intravenous-appli-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Pedram Rafiei, Azita Haddadi Division of Pharmacy, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada Abstract: Docetaxel is a highly potent anticancer agent being used in a wide spectrum of cancer types. There are important matters of concern regarding the drug’s pharmacokinetics related to the conventional formulation. Poly(lactide-co-glycolide) (PLGA) is a biocompatible/biodegradable polymer with variable physicochemical characteristics, and its application in human has been approved by the United States Food and Drug Administration. PLGA gives polymeric nanoparticles with unique drug delivery characteristics. The application of PLGA nanoparticles (NPs) as intravenous (IV) sustained-release delivery vehicles for docetaxel can favorably modify pharmacokinetics, biofate, and pharmacotherapy of the drug in cancer patients. Surface modification of PLGA NPs with poly(ethylene glycol) (PEG) can further enhance NPs’ long-circulating properties. Herein, an optimized fabrication approach has been used for the preparation of PLGA and PLGA–PEG NPs loaded with docetaxel for IV application. Both types of NP formulations demonstrated in vitro characteristics that were considered suitable for IV administration (with long-circulating sustained-release purposes). NP formulations were IV administered to an animal model, and docetaxel’s pharmacokinetic and biodistribution profiles were determined and compared between study groups. PLGA and PEGylated PLGA NPs were able to modify the pharmacokinetics and biodistribution of docetaxel. Accordingly, the mode of changes made to pharmacokinetics and biodistribution of docetaxel is attributed to the size and surface properties of NPs. NPs contributed to increased blood residence time of docetaxel fulfilling their role as long-circulating sustained-release drug delivery systems. Surface modification of NPs contributed to more pronounced docetaxel blood concentration, which confirms the role of PEG in conferring long-circulation properties to NPs. Keywords: poly(lactide-co-glycolide), poly(lactide-co-glycolide)–poly(ethylene glycol), polymeric nanoparticles, docetaxel, emulsification solvent evaporation, sustained release, pharmacokinetics, biodistributionRafiei PHaddadi ADove Medical PressarticlePoly (lactide-co-glycolide) (PLGA)poly (lactide-co-glycolide)-poly (ethylene glycol) (PLGA-PEG)polymeric nanoparticlesdocetaxelemulsification solvent evaporationsustained releasePharmacokineticsbio-distribution.Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 935-947 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Poly (lactide-co-glycolide) (PLGA) poly (lactide-co-glycolide)-poly (ethylene glycol) (PLGA-PEG) polymeric nanoparticles docetaxel emulsification solvent evaporation sustained release Pharmacokinetics bio-distribution. Medicine (General) R5-920
spellingShingle	Poly (lactide-co-glycolide) (PLGA) poly (lactide-co-glycolide)-poly (ethylene glycol) (PLGA-PEG) polymeric nanoparticles docetaxel emulsification solvent evaporation sustained release Pharmacokinetics bio-distribution. Medicine (General) R5-920 Rafiei P Haddadi A Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile
description	Pedram Rafiei, Azita Haddadi Division of Pharmacy, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada Abstract: Docetaxel is a highly potent anticancer agent being used in a wide spectrum of cancer types. There are important matters of concern regarding the drug’s pharmacokinetics related to the conventional formulation. Poly(lactide-co-glycolide) (PLGA) is a biocompatible/biodegradable polymer with variable physicochemical characteristics, and its application in human has been approved by the United States Food and Drug Administration. PLGA gives polymeric nanoparticles with unique drug delivery characteristics. The application of PLGA nanoparticles (NPs) as intravenous (IV) sustained-release delivery vehicles for docetaxel can favorably modify pharmacokinetics, biofate, and pharmacotherapy of the drug in cancer patients. Surface modification of PLGA NPs with poly(ethylene glycol) (PEG) can further enhance NPs’ long-circulating properties. Herein, an optimized fabrication approach has been used for the preparation of PLGA and PLGA–PEG NPs loaded with docetaxel for IV application. Both types of NP formulations demonstrated in vitro characteristics that were considered suitable for IV administration (with long-circulating sustained-release purposes). NP formulations were IV administered to an animal model, and docetaxel’s pharmacokinetic and biodistribution profiles were determined and compared between study groups. PLGA and PEGylated PLGA NPs were able to modify the pharmacokinetics and biodistribution of docetaxel. Accordingly, the mode of changes made to pharmacokinetics and biodistribution of docetaxel is attributed to the size and surface properties of NPs. NPs contributed to increased blood residence time of docetaxel fulfilling their role as long-circulating sustained-release drug delivery systems. Surface modification of NPs contributed to more pronounced docetaxel blood concentration, which confirms the role of PEG in conferring long-circulation properties to NPs. Keywords: poly(lactide-co-glycolide), poly(lactide-co-glycolide)–poly(ethylene glycol), polymeric nanoparticles, docetaxel, emulsification solvent evaporation, sustained release, pharmacokinetics, biodistribution
format	article
author	Rafiei P Haddadi A
author_facet	Rafiei P Haddadi A
author_sort	Rafiei P
title	Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile
title_short	Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile
title_full	Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile
title_fullStr	Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile
title_full_unstemmed	Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile
title_sort	docetaxel-loaded plga and plga-peg nanoparticles for intravenous application: pharmacokinetics and biodistribution profile
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/3411511e40d34317aeb3db91e9526674
work_keys_str_mv	AT rafieip docetaxelloadedplgaandplgapegnanoparticlesforintravenousapplicationpharmacokineticsandbiodistributionprofile AT haddadia docetaxelloadedplgaandplgapegnanoparticlesforintravenousapplicationpharmacokineticsandbiodistributionprofile
_version_	1718402032281321472

Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile

Ejemplares similares